Risk trajectories of complications in over one thousand newly diagnosed individuals with type 2 diabetes
- PMID: 35821071
- PMCID: PMC9276720
- DOI: 10.1038/s41598-022-16135-0
Risk trajectories of complications in over one thousand newly diagnosed individuals with type 2 diabetes
Abstract
Although the increased risk of complications of type 2 diabetes (T2D) is well known, there is still little information about the long-term development of comorbidities in relation to risk factors. The purpose of the present study was to describe the risk trajectories of T2D complications over time in an observational cohort of newly diagnosed T2D patients, as well as to evaluate the effect of common risk factors on the development of comorbidities. This national cohort study investigated individuals with T2D in the Swedish National Diabetes Register regarding prevalence of comorbidities at the time of diagnosis, and the incidence of cardiovascular disease (CVD), chronic kidney disease (CKD) and heart failure in the entire patient cohort and stratified by HbA1c levels and age at baseline. Multivariable Cox regressions were used to evaluate risk factors predicting outcomes. We included 100,878 individuals newly diagnosed with T2D between 1998 and 2012 in the study, with mean 5.5 years follow-up (max 17 years). The mean age at diagnosis was 62.6 ± SD12.5 years and 42.7% of the patients were women. Prevalent CVD was reported for 17.5% at baseline. Although the prevalence of comorbidities was generally low for individuals 50 years or younger at diagnosis, the cumulative incidence of the investigated comorbidities increased over time. Newly diagnosed CVD was the most common comorbidity. Women were shown to have a lower risk of developing comorbid conditions than men. When following the risk trajectory of comorbidities over a period of up to 15 years in individuals with type 2 diabetes, we found that all comorbidities gradually increased over time. There was no distinct time point when onset suddenly increased.
© 2022. The Author(s).
Conflict of interest statement
Professor Eliasson reports personal fees (expert panels, lectures) from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Mundipharma, Navamedic, NovoNordisk, RLS Global, and grants and personal fees from Sanofi, all outside the submitted work. Gudrun Höskuldsdóttir, Stefan Franzén and Katarina Eeg-Olofsson report no competing interests.
Figures

Similar articles
-
Cardiovascular and Renal Outcomes in Patients with Type-2 Diabetes and Chronic Kidney Disease Identified in a United States Administrative Claims Database: A Population Cohort Study.Nephron. 2021;145(4):342-352. doi: 10.1159/000513782. Epub 2021 Mar 31. Nephron. 2021. PMID: 33789294
-
Chronic kidney disease among US adults with type 2 diabetes and cardiovascular diseases: A national estimate of prevalence by KDIGO 2012 classification.Diabetes Metab Syndr. 2019 Jan-Feb;13(1):612-615. doi: 10.1016/j.dsx.2018.11.026. Epub 2018 Nov 3. Diabetes Metab Syndr. 2019. PMID: 30641775
-
Prevalence and incidence density rates of chronic comorbidity in type 2 diabetes patients: an exploratory cohort study.BMC Med. 2012 Oct 29;10:128. doi: 10.1186/1741-7015-10-128. BMC Med. 2012. PMID: 23106808 Free PMC article.
-
Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.Postgrad Med. 2022 May;134(4):376-387. doi: 10.1080/00325481.2021.2009726. Epub 2021 Dec 29. Postgrad Med. 2022. PMID: 34817311 Review.
-
Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review.Endocrine. 2020 Dec;70(3):441-453. doi: 10.1007/s12020-020-02444-9. Epub 2020 Aug 10. Endocrine. 2020. PMID: 32779091 Free PMC article. Review.
Cited by
-
Comparison of clinical characteristics and disease burden between early- and late-onset type 2 diabetes patients: a population-based cohort study.BMC Public Health. 2023 Dec 4;23(1):2411. doi: 10.1186/s12889-023-17280-5. BMC Public Health. 2023. PMID: 38049796 Free PMC article.
-
Determinants of early chronic kidney disease in patients with recently diagnosed type 2 diabetes mellitus: a retrospective study from the Taiwan Diabetes Registry.BMC Nephrol. 2024 Apr 15;25(1):133. doi: 10.1186/s12882-024-03567-1. BMC Nephrol. 2024. PMID: 38622535 Free PMC article.
-
Modeling of Disease Progression of Type 2 Diabetes Using Real-World Data: Quantifying Competing Risks of Morbidity and Mortality.CPT Pharmacometrics Syst Pharmacol. 2025 Mar;14(3):606-615. doi: 10.1002/psp4.13301. Epub 2025 Jan 17. CPT Pharmacometrics Syst Pharmacol. 2025. PMID: 39825570 Free PMC article.
-
Heterogeneity in the development of diabetes-related complications: narrative review of the roles of ancestry and geographical determinants.Diabetologia. 2025 Jul 22. doi: 10.1007/s00125-025-06482-8. Online ahead of print. Diabetologia. 2025. PMID: 40696182 Review.
References
-
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 352(9131), 837–53 (1998). - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical